newsfilter
← Latest News
GlobeNewswire·

CORRECTION: MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

BRISBANE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, August 3rd by MyoKardia, Inc. (Nasdaq: MYOK), please note that the second quote by Jeffrey...